Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Pharmacol.

Sec. Ethnopharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1693131

Targeting Type H Vessels with Bioactive Metabolites from Traditional Chinese Botanical Drugs: A Therapeutic Strategy for Skeletal Disorders

Provisionally accepted
Shengping  TangShengping Tang1Jinkao  LiJinkao Li2Zhuqing  DongZhuqing Dong1Yangjie  CaiYangjie Cai1Jianwei  HuJianwei Hu1Ding  XiaofeiDing Xiaofei1Shijie  LiaoShijie Liao1*
  • 1First Affiliated Hospital, Guangxi Medical University, Nanning, China
  • 2The Second Affiliated Hospital of Guangxi Medical University, Nanning, China

The final, formatted version of the article will be published soon.

Type H vessels are a specialized subtype of bone capillaries, first identified in 2014, characterized by high co-expression of CD31 and Endomucin. These vessels play a key regulatory role in bone development, repair, and remodeling through angiogenesis–osteogenesis coupling, which is essential for maintaining skeletal homeostasis. Type H vessels are abundant in the bones of young individuals but gradually decline with age, and their dysregulation is closely associated with skeletal disorders, including osteoporosis, osteoarthritis, bone defects, fractures, and osteonecrosis of the femoral head. Previous studies have identified the molecular mechanisms underlying the regulation of type H vessels, and recent investigations have examined pharmacological strategies to modulate these pathways. Among these, bioactive metabolites derived from traditional Chinese botanical drugs have attracted attention for their ability to regulate type H vessel formation and improve skeletal health. This review summarizes the molecular mechanisms by which these bioactive metabolites target type H vessels, highlighting their therapeutic potential in skeletal disorders and suggesting that modulation of type H vessel formation represents a promising strategy for intervention. Future studies are needed to further clarify the mechanisms of action of these metabolites and to assess their safety and clinical efficacy for translation into human therapy.

Keywords: Bioactive metabolites, type H vessels, Osteoporosis, Osteoarthritis, Bone defects, Fracture, Osteonecrosis of the femoral head

Received: 26 Aug 2025; Accepted: 15 Oct 2025.

Copyright: © 2025 Tang, Li, Dong, Cai, Hu, Xiaofei and Liao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Shijie Liao, liaoshijie@sr.gxmu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.